Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17059157 | METHODS AND SYSTEMS FOR IMPROVED MAJOR HISTOCOMPATIBILITY COMPLEX (MHC)-PEPTIDE BINDING PREDICTION OF NEOEPITOPES USING A RECURRENT NEURAL NETWORK ENCODER AND ATTENTION WEIGHTING | November 2020 | August 2022 | Allow | 21 | 3 | 0 | Yes | No |
| 17067671 | METHOD FOR DETERMINING LENS AND APPARATUS USING THE METHOD | October 2020 | July 2022 | Allow | 21 | 4 | 1 | Yes | No |
| 17004675 | Optical Methods and Systems For DNA Assembly For Computer Data Storage | August 2020 | January 2024 | Allow | 40 | 2 | 0 | No | No |
| 16995513 | SYSTEM AND METHOD FOR PLANNING A PATIENT-SPECIFIC CARDIAC PROCEDURE | August 2020 | May 2024 | Allow | 45 | 2 | 0 | No | No |
| 16940922 | DETECTION OF DNA THAT ORIGINATES FROM A SPECIFIC CELL-TYPE AND RELATED METHODS | July 2020 | December 2023 | Allow | 40 | 3 | 1 | Yes | No |
| 16907034 | MICROSATELLITE INSTABILITY DETECTION IN CELL-FREE DNA | June 2020 | August 2023 | Allow | 37 | 3 | 0 | No | No |
| 16713680 | ITERATIVE DISCOVERY OF NEOEPITOPES AND ADAPTIVE IMMUNOTHERAPY AND METHODS THEREFOR | December 2019 | February 2023 | Allow | 38 | 2 | 0 | No | No |
| 16695489 | METHODS AND SYSTEMS FOR PREDICTING SENSITIVITY OF BLOOD FLOW CALCULATIONS TO CHANGES IN ANATOMICAL GEOMETRY | November 2019 | March 2023 | Allow | 40 | 1 | 0 | No | No |
| 16681448 | Biomarkers and Methods for Measuring and Monitoring Inflammatory Disease Activity | November 2019 | September 2024 | Abandon | 58 | 1 | 0 | No | No |
| 16609282 | METHODS FOR DIAGNOSING OR PREDICTING CHRONIC BRONCHITIS | October 2019 | April 2024 | Allow | 54 | 2 | 0 | No | No |
| 16540440 | SYSTEM AND METHOD FOR VASCULAR TREE GENERATION USING PATIENT-SPECIFIC STRUCTURAL AND FUNCTIONAL DATA, AND JOINT PRIOR INFORMATION | August 2019 | March 2023 | Allow | 43 | 1 | 0 | No | No |
| 16422568 | VIRAL NEOEPITOPES AND USES THEREOF | May 2019 | April 2024 | Allow | 59 | 2 | 0 | No | No |
| 16396087 | SYSTEMS AND METHODS FOR PROVIDING PERSONALIZED ESTIMATES OF BIOHEAT TRANSFER | April 2019 | September 2024 | Abandon | 60 | 2 | 0 | No | No |
| 16362975 | WIRELESS PHYSIOLOGICAL SENSOR PATCHES AND SYSTEMS | March 2019 | December 2023 | Abandon | 56 | 3 | 0 | Yes | No |
| 16361016 | ANALYZING AND USING MOTILITY KINEMATICS OF MICROORGANISMS | March 2019 | April 2023 | Allow | 49 | 2 | 0 | Yes | No |
| 16292608 | ANALYZING AND USING MOTILITY KINEMATICS OF MICROORGANISMS | March 2019 | January 2023 | Allow | 47 | 1 | 0 | No | No |
| 16241621 | SYSTEMS AND METHODS FOR DETERMINATION OF BLOOD FLOW CHARACTERISTICS AND PATHOLOGIES THROUGH MODELING OF MYOCARDIAL BLOOD SUPPLY | January 2019 | October 2024 | Abandon | 60 | 3 | 0 | Yes | No |
| 16217328 | Patient-Specific Modeling of Hemodynamic Parameters in Coronary Arteries | December 2018 | September 2023 | Allow | 57 | 2 | 0 | Yes | No |
| 16209683 | PLASMA BASED PROTEIN PROFILING FOR EARLY STAGE LUNG CANCER DIAGNOSIS | December 2018 | May 2023 | Allow | 53 | 6 | 1 | Yes | No |
| 16168618 | METHOD AND SYSTEM FOR GENOME IDENTIFICATION | October 2018 | November 2022 | Abandon | 49 | 1 | 0 | No | No |
| 16142554 | ITERATIVE MEDICAL TESTING OF BIOLOGICAL SAMPLES | September 2018 | January 2023 | Allow | 52 | 2 | 0 | Yes | No |
| 16122328 | SYSTEMS AND METHODS FOR PREDICTING LOCATION, ONSET, AND/OR CHANGE OF CORONARY LESIONS | September 2018 | March 2023 | Allow | 54 | 1 | 0 | No | No |
| 16041810 | SYSTEM AND METHOD FOR POLYGENIC PHENOTYPIC TRAIT PREDISPOSITION ASSESSMENT USING A COMBINATION OF DYNAMIC NETWORK ANALYSIS AND MACHINE LEARNING | July 2018 | April 2024 | Abandon | 60 | 2 | 1 | No | No |
| 16039276 | METHOD AND SYSTEM FOR CHARACTERIZATION FOR APPENDIX-RELATED CONDITIONS ASSOCIATED WITH MICROORGANISMS | July 2018 | December 2022 | Abandon | 53 | 6 | 1 | Yes | No |
| 16032990 | METHODS AND DEVICES FOR DETERMINING OPTIMAL AGENT DOSAGES | July 2018 | March 2023 | Abandon | 56 | 1 | 1 | No | No |
| 16017557 | DRUG DISCOVERY METHODS | June 2018 | December 2022 | Abandon | 54 | 0 | 1 | No | No |
| 15995966 | THE PLASMA METABOLOME AS A PREDICTOR OF BIOLOGICAL AGING | June 2018 | May 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 15991097 | SYSTEMS AND METHODS FOR ASSESSMENT OF TISSUE FUNCTION BASED ON VASCULAR DISEASE | May 2018 | November 2022 | Allow | 54 | 2 | 0 | Yes | No |
| 15983906 | COMPOSITIONS AND METHODS FOR DIAGNOSING COLON DISORDERS | May 2018 | November 2023 | Abandon | 60 | 2 | 1 | No | No |
| 15764203 | BIOLOGICAL TISSUE FABRICATION INFORMATION GENERATING DEVICE, BIOLOGICAL TISSUE FABRICATION SYSTEM, AND MEDICAL EXPENSE CALCULATION SYSTEM | March 2018 | June 2023 | Allow | 60 | 2 | 0 | Yes | No |
| 15763056 | BIOMARKERS FOR ASSESSING SUBJECTS WITH MULTIPLE SCLEROSIS | March 2018 | April 2023 | Allow | 60 | 2 | 1 | No | No |
| 15924745 | BIOMARKER QUANTIFICATION IN A TISSUE SAMPLE | March 2018 | September 2022 | Allow | 54 | 1 | 1 | Yes | No |
| 15898543 | Technique for Identifying Features | February 2018 | January 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 15885463 | MODIFIED FBA IN A PRODUCTION NETWORK | January 2018 | August 2022 | Allow | 55 | 2 | 1 | Yes | No |
| 15872035 | DETECTION AND VISUALIZATION OF MUTATIONAL EVOLUTION DEPENDENT GENE SET ALTERATION | January 2018 | November 2022 | Abandon | 58 | 4 | 0 | Yes | No |
| 15853314 | Base Coverage Normalization and Use Thereof in Detecting Copy Number Variation | December 2017 | June 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 15841477 | SYSTEM AND METHOD FOR IMPROVED ESTIMATION OF FUNCTIONAL POTENTIAL OF GENOMES AND METAGENOMES | December 2017 | August 2022 | Allow | 56 | 1 | 1 | No | No |
| 15717777 | FORECASTING MACROPHAGE ACTIVATION SYNDROMES | September 2017 | December 2022 | Allow | 60 | 2 | 0 | Yes | No |
| 15484059 | SYSTEM AND METHOD FOR BLOOD AND SALIVA OPTIMIZED FOOD CONSUMPTION AND DELIVERY | April 2017 | February 2024 | Allow | 60 | 8 | 1 | Yes | No |
| 15502924 | SYSTEMS AND METHODS FOR TRACKING AND IDENTIFYING INFECTION TRANSMISSION | February 2017 | September 2024 | Abandon | 60 | 6 | 0 | No | Yes |
| 15349375 | SYSTEMS AND METHODS FOR GENOTYPE-DERIVED DRUG RECOMMENDATIONS | November 2016 | December 2022 | Abandon | 60 | 6 | 0 | Yes | No |
| 15292095 | Compositions And Methods For Viral Cancer Neoepitopes | October 2016 | December 2022 | Allow | 60 | 8 | 0 | Yes | Yes |
| 15292021 | Systems, Compositions, And Methods For Discovery Of MSI And Neoepitopes That Predict Sensitivity To Checkpoint Inhibitors | October 2016 | October 2019 | Abandon | 36 | 8 | 0 | Yes | Yes |
| 15213165 | PHYSIOLOGICAL IMAGERY GENERATOR SYSTEM AND METHOD | July 2016 | August 2023 | Abandon | 60 | 6 | 0 | No | Yes |
| 15197172 | METHODS AND APPARATUSES FOR CONDUCTING ANALYSES | June 2016 | November 2023 | Abandon | 60 | 12 | 1 | Yes | No |
| 15037394 | POLYMORPHIC GENE TYPING AND SOMATIC CHANGE DETECTION USING SEQUENCING DATA | May 2016 | March 2023 | Allow | 60 | 5 | 1 | Yes | No |
| 15026884 | SYSTEM AND METHOD OF PREDICTING PERSONAL THERAPEUTIC RESPONSE | April 2016 | October 2022 | Abandon | 60 | 6 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CLOW, LORI A.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CLOW, LORI A works in Art Unit 1671 and has examined 47 patent applications in our dataset. With an allowance rate of 63.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 56 months.
Examiner CLOW, LORI A's allowance rate of 63.8% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by CLOW, LORI A receive 3.30 office actions before reaching final disposition. This places the examiner in the 89% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CLOW, LORI A is 56 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +12.1% benefit to allowance rate for applications examined by CLOW, LORI A. This interview benefit is in the 47% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 15.9% of applications are subsequently allowed. This success rate is in the 14% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 18.8% of cases where such amendments are filed. This entry rate is in the 24% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 33.3% of appeals filed. This is in the 4% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 87.5% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.